Skip to Content

Halobetasol Topical Dosage

Applies to the following strength(s): 0.05%

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Dermatitis

Apply a thin layer to affected area once or twice a day

Comments:
-Treatment should be limited to two weeks.
-Use should be limited to 50 g a week.
-Use should be discontinued when control is achieved.
-Reassessment of diagnosis may be needed, if no improvement is seen in two weeks.
-This topical drug should not be used with occlusive dressings.

Use: Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Usual Adult Dose for Eczema

Apply a thin layer to affected area once or twice a day

Comments:
-Treatment should be limited to two weeks.
-Use should be limited to 50 g a week.
-Use should be discontinued when control is achieved.
-Reassessment of diagnosis may be needed, if no improvement is seen in two weeks.
-This topical drug should not be used with occlusive dressings.

Use: Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Usual Adult Dose for Psoriasis

Apply a thin layer to affected area once or twice a day

Comments:
-Treatment should be limited to two weeks.
-Use should be limited to 50 g a week.
-Use should be discontinued when control is achieved.
-Reassessment of diagnosis may be needed, if no improvement is seen in two weeks.
-This topical drug should not be used with occlusive dressings.

Use: Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Usual Pediatric Dose for Dermatitis

12 years or older:
Apply a thin layer to affected area once or twice a day

Comments:
-Treatment should be limited to two weeks.
-Use should be limited to 50 g a week.
-Use should be discontinued when control is achieved.
-Reassessment of diagnosis may be needed, if no improvement is seen in two weeks.
-This topical drug should not be used with occlusive dressings.

Use: Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Usual Pediatric Dose for Eczema

12 years or older:
Apply a thin layer to affected area once or twice a day

Comments:
-Treatment should be limited to two weeks.
-Use should be limited to 50 g a week.
-Use should be discontinued when control is achieved.
-Reassessment of diagnosis may be needed, if no improvement is seen in two weeks.
-This topical drug should not be used with occlusive dressings.

Use: Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Usual Pediatric Dose for Psoriasis

12 years or older:
Apply a thin layer to affected area once or twice a day

Comments:
-Treatment should be limited to two weeks.
-Use should be limited to 50 g a week.
-Use should be discontinued when control is achieved.
-Reassessment of diagnosis may be needed, if no improvement is seen in two weeks.
-This topical drug should not be used with occlusive dressings.

Use: Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Rub in gently and completely
-This topical drug should not be used on the face, groin, or in the axillae.
-Contact with the eyes should be avoided.
-The treated area should not be bandaged, or otherwise covered or wrapped, so as to be occlusive unless directed by a healthcare professional.

Monitoring:
-Endocrine: HPA-axis suppression (Urinary free-cortisol test, ACTH-stimulation test)

Patient advice:
-Patients should report any signs of local adverse reactions, especially those that develop under occlusive dressings.

Hide